Recommended Topic Related To:

Velcade

"Dec. 12, 2012 -- Heavy coffee drinkers -- those who drink more than four cups a day -- may cut their risk of dying from cancers of the mouth and throat by nearly half, according to new research.

"We examined coffee drinking habits in "...

Velcade

Velcade

CLINICAL PHARMACOLOGY

Mechanism of Action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro . Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.

Pharmacodynamics

Following twice weekly administration of 1 mg/m²and 1.3 mg/m²bortezomib doses (n=12 per each dose level), the maximum inhibition of 20S proteasome activity (relative to baseline) in whole blood was observed 5 minutes after drug administration. Comparable maximum inhibition of 20S proteasome activity was observed between 1 and 1.3 mg/m²doses. Maximal inhibition ranged from 70% to 84% and from 73% to 83% for the 1 mg/m²and 1.3 mg/m²dose regimens, respectively.

Pharmacokinetics

Following intravenous administration of 1 mg/m²and 1.3 mg/m²doses to 24 patients with multiple myeloma (n=12, per each dose level), the mean maximum plasma concentrations of bortezomib (Cmax) after the first dose (Day 1) were 57 and 112 ng/mL, respectively. In subsequent doses, when administered twice weekly, the mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1 mg/m²dose and 89 to 120 ng/mL for the 1.3 mg/m²dose. The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m²dose and 76 to 108 hours after the 1.3mg/m²dose. The mean total body clearances was 102 and 112 L/h following the first dose for doses of 1 mg/m²and 1.3 mg/m², respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1 and 1.3 mg/m², respectively.

Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m²dose to patients (n = 14 for intravenous, n = 17 for subcutaneous) with multiple myeloma, the total systemic exposure after repeat dose administration (AUClast) was equivalent for subcutaneous and intravenous administration. The Cmax after subcutaneous administration (20.4 ng/mL) was lower than intravenous (223 ng/mL). The AUClast geometric mean ratio was 0.99 and 90% confidence intervals were 80.18% - 122.80%.

Distribution

The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/m²following single- or repeat-dose administration of 1 mg/m²or 1.3mg/m²to patients with multiple myeloma. This suggests bortezomib distributes widely to peripheral tissues. The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL.

Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2. Bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated bortezomib metabolites are inactive as 26S proteasome inhibitors. Pooled plasma data from 8 patients at 10 min and 30 min after dosing indicate that the plasma levels of metabolites are low compared to the parent drug.

Elimination

The pathways of elimination of bortezomib have not been characterized in humans.

Age

Analyses of data after the first dose of Cycle 1 (Day 1) in 39 multiple myeloma patients who had received intravenous doses of 1 mg/m²and 1.3 mg/m²showed that both dose-normalized AUC and Cmax tend to be less in younger patients. Patients < 65 years of age (n=26) had about 25% lower mean dose-normalized AUC and Cmax than those ≥ 65 years of age (n=13).

Gender

Mean dose-normalized AUC and Cmax values were comparable between male (n=22) and female (n=17) patients after the first dose of Cycle 1 for the 1 and 1.3 mg/m²doses.

Race

The effect of race on exposure to bortezomib could not be assessed as most of the patients were Caucasian.

Hepatic Impairment

The effect of hepatic impairment (see Table 4 for definition of hepatic impairment) on the pharmacokinetics of bortezomib was assessed in 60 patients with cancer at bortezomib doses ranging from 0.5 to 1.3 mg/m². When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalized bortezomib AUC. However, the dose-normalized mean AUC values were increased by approximately 60% in patients with moderate or severe hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment, and those patients should be monitored closely [see DOSAGE AND ADMINISTRATION and Use in Specific Populations].

Renal Impairment

A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCl) into the following groups: Normal (CrCl ≥ 60 mL/min/1.73 m², N=12), Mild (CrCl=40-59 mL/min/1.73 m², N=10), Moderate (CrCl=20-39 mL/min/1.73 m², N=9), and Severe (CrCl < 20 mL/min/1.73 m², N=3). A group of dialysis patients who were dosed after dialysis was also included in the study (N=8). Patients were administered intravenous doses of 0.7 to 1.3 mg/m²of bortezomib twice weekly. Exposure of bortezomib (dose-normalized AUC and Cmax) was comparable among all the groups [see Use in Specific Populations].

Pediatric

There are no pharmacokinetic data in pediatric patients.

Cytochrome P450

Bortezomib is a poor inhibitor of human liver microsome cytochrome P450 1A2, 2C9, 2D6, and 3A4, with IC50 values of > 30μM ( > 11.5μg/mL). Bortezomib may inhibit 2C19 activity (IC50 = 18 μM, 6.9 μg/mL) and increase exposure to drugs that are substrates for this enzyme. Bortezomib did not induce the activities of cytochrome P450 3A4 and 1A2 in primary cultured human hepatocytes.

Animal Toxicology and/or Pharmacology

Cardiovascular Toxicity

Studies in monkeys showed that administration of dosages approximately twice the recommended clinical dose resulted in heart rate elevations, followed by profound progressive hypotension, bradycardia, and death 12 to 14 hours post dose. Doses ≥ 1.2 mg/m²induced dose-proportional changes in cardiac parameters. Bortezomib has been shown to distribute to most tissues in the body, including the myocardium. In a repeated dosing toxicity study in the monkey, myocardial hemorrhage, inflammation, and necrosis were also observed.

Chronic Administration

In animal studies at a dose and schedule similar to that recommended for patients (twice weekly dosing for 2 weeks followed by 1-week rest), toxicities observed included severe anemia and thrombocytopenia, and gastrointestinal, neurological and lymphoid system toxicities. Neurotoxic effects of bortezomib in animal studies included axonal swelling and degeneration in peripheral nerves, dorsal spinal roots, and tracts of the spinal cord. Additionally, multifocal hemorrhage and necrosis in the brain, eye, and heart were observed.

Clinical Studies

Multiple Myeloma

Randomized, Open-Label Clinical Study in Patients with Previously Untreated Multiple Myeloma

A prospective, international, randomized (1:1), open-label clinical study of 682 patients was conducted to determine whether VELCADE administered intravenously (1.3 mg/m²) in combination with melphalan (9 mg/m²) and prednisone (60 mg/m²) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m²) and prednisone (60 mg/m²) in patients with previously untreated multiple myeloma. Treatment was administered for a maximum of 9 cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity. Antiviral prophylaxis was recommended for patients on the VELCADE study arm.

The median age of the patients in the study was 71 years (48;91), 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80 (60;100). Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/L (64;165), and a median platelet count of 221,500 /microliter (33,000;587,000).

Efficacy results for the trial are presented in Table 11. At a pre-specified interim analysis (with median follow-up of 16.3 months), the combination of VELCADE, melphalan and prednisone therapy resulted in significantly superior results for time to progression, progression-free survival, overall survival and response rate. Further enrollment was halted, and patients receiving melphalan and prednisone were offered VELCADE in addition. A later, pre-specified analysis of overall survival (with median follow-up of 36.7 months with a hazard ratio of 0.65, 95% CI: 0.51, 0.84) resulted in a statistically significant survival benefit for the VELCADE, melphalan and prednisone treatment arm despite subsequent therapies including VELCADE based regimens. In an updated analysis of overall survival based on 387 deaths (median follow-up 60.1 months), the median overall survival for the VELCADE, melphalan and prednisone treatment arm was 56.4 months and for the melphalan and prednisone treatment arm was 43.1 months, with a hazard ratio of 0.695 (95% CI: 0.57, 0.85).

Table 11: Summary of Efficacy Analyses in the Previously Untreated Multiple Myeloma Study

Efficacy Endpoint VELCADE,
Melphalan and Prednisone
n=344
Melphalan and Prednisone
n=338
Time to Progression
Events n (%) 101 (29) 152 (45)
Mediana (months) (95% CI) 20.7 (17.6, 24.7) 15.0 (14.1, 17.9)
Hazard ratiob(95% CI) 0.54 (0.42, 0.70)
p-value c 0.000002
Progression-free Survival
Events n (%) 135 (39) 190 (56)
Mediana (months) (95% CI) 18.3 (16.6, 21.7) 14.0 (11.1, 15.0)
Hazard ratiob (95% CI) 0.61 (0.49, 0.76)
p-value c 0.00001
Response Rate
CRd n (%) 102 (30) 12 (4)
PRd n (%) 136 (40) 103 (30)
nCR n (%) 5 (1) 0
CR + PRd n (%) 238 (69) 115 (34)
p-valuee < 10-10
Overall Survival at median follow up of 36.7 months
Events (deaths) n (%) 109 (32) 148 (44)
Mediana (months) (95% CI) Not Reached (46.2, NR) 43.1 (34.8, NR)
Hazard ratiob (95% CI) 0.65 (0.51, 0.84)
p-value c 0.00084
Note: All results are based on the analysis performed at a median follow-up duration of 16.3 months except for the overall survival analysis.
aKaplan-Meier estimate
bHazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: beta2-microglobulin, albumin, and region. A hazard ratio less than 1 indicates an advantage for VELCADE, melphalan and prednisone
cp-value based on the stratified log-rank test adjusted for stratification factors: beta2-microglobulin, albumin, and region
dEBMT criteria
ep-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors

TTP was statistically significantly longer on the VELCADE, melphalan and prednisone arm (see Figure 1). (median follow-up 16.3 months)

Figure 1: Time to Progression
VELCADE, Melphalan and Prednisone versus Melphalan and Prednisone

Time to ProgressionVELCADE, Melphalan and Prednisone versus Melphalan and Prednisone - Illustration

Overall survival was statistically significantly longer on the VELCADE, melphalan and prednisone arm (see Figure 2). Median follow – up 60.1 months)

Figure 2 : Overall Survival
VELCADE, Melphalan and Prednisone versus Melphalan and Prednisone

Overall Survival  - Illustration

Randomized, Clinical Study in Relapsed Multiple Myeloma of VELCADE versus Dexamethasone

A prospective phase 3, international, randomized (1:1), stratified, open-label clinical study enrolling 669 patients was designed to determine whether VELCADE resulted in improvement in time to progression (TTP) compared to high-dose dexamethasone in patients with progressive multiple myeloma following 1 to 3 prior therapies. Patients considered to be refractory to prior high-dose dexamethasone were excluded as were those with baseline Grade ≥ 2 peripheral neuropathy or platelet counts < 50,000/μL. A total of 627 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had previously received (1 previous line versus more than 1 line of therapy), time of progression relative to prior treatment (progression during or within 6 months of stopping their most recent therapy versus relapse > 6 months after receiving their most recent therapy), and screening β2-microglobulin levels ( ≤ 2.5 mg/L versus > 2.5 mg/L).

Baseline patient and disease characteristics are summarized in Table 12.

Table 12: Summary of Baseline Patient and Disease Characteristics in the Relapsed Multiple Myeloma Study

  VELCADE
N=333
Dexamethasone
N=336
Patient Characteristics
  Median age in years (range) 62.0 (33, 84) 61.0 (27, 86)
  Gender: Male/female 56% / 44% 60% / 40%
  Race: Caucasian/black/other 90% / 6% / 4% 88% / 7% / 5%
  Karnofsky performance status score ≤ 70 13% 17%
  Hemoglobin < 100 g/L 32% 28%
  Platelet count < 75 x 109/L 6% 4%
Disease Characteristics
  Type of myeloma (%):  IgG/IgA/Light chain 60% / 23% / 12% 59% / 24% / 13%
  Median p2-microglobulin (mg/L) 3.7 3.6
  Median albumin (g/L) 39.0 39.0
  Creatinine clearance ≤ 30 mL/min [n (%)] 17 (5%) 11 (3%)
Median Duration of Multiple Myeloma Since
  Diagnosis (Years) 3.5 3.1
Number of Prior Therapeutic Lines of Treatment
  Median 2 2
  1 prior line 40% 35%
   > 1 prior line 60% 65%
Previous Therapy
  Any prior steroids, e.g., dexamethasone, VAD 98% 99%
  Any prior anthracyclines, e.g., VAD, mitoxantrone 77% 76%
  Any prior alkylating agents, e.g., MP, VBMCP 91% 92%
  Any prior thalidomide therapy 48% 50%
  Vinca alkaloids 74% 72%
  Prior stem cell transplant/other high-dose therapy 67% 68%
  Prior experimental or other types of therapy 3% 2%

Patients in the VELCADE treatment group were to receive eight 3-week treatment cycles followed by three 5week treatment cycles of VELCADE. Patients achieving a CR were treated for 4 cycles beyond first evidence of CR. Within each 3-week treatment cycle, VELCADE 1.3 mg/m²/dose alone was administered by intravenous bolus twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21).

Within each 5-week treatment cycle, VELCADE 1.3 mg/m²/dose alone was administered by intravenous bolus once weekly for 4 weeks on Days 1, 8, 15, and 22 followed by a 13-day rest period (Days 23 to 35) [see DOSAGE AND ADMINISTRATION].

Patients in the dexamethasone treatment group were to receive four 5-week treatment cycles followed by five 4week treatment cycles. Within each 5-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4, 9 to 12, and 17 to 20 followed by a 15-day rest period (Days 21-35). Within each 4week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4 followed by a 24-day rest period (Days 5 to 28). Patients with documented progressive disease on dexamethasone were offered VELCADE at a standard dose and schedule on a companion study. Following a preplanned interim analysis of time to progression, the dexamethasone arm was halted and all patients randomized to dexamethasone were offered VELCADE, regardless of disease status.

In the VELCADE arm, 34% of patients received at least one VELCADE dose in all 8 of the 3-week cycles of therapy, and 13% received at least one dose in all 11 cycles. The average number of VELCADE doses during the study was 22, with a range of 1 to 44. In the dexamethasone arm, 40% of patients received at least one dose in all 4 of the 5-week treatment cycles of therapy, and 6% received at least one dose in all 9 cycles.

The time to event analyses and response rates from the relapsed multiple myeloma study are presented in Table 13. Response and progression were assessed using the European Group for Blood and Marrow Transplantation (EBMT) criteria. Complete response (CR) required < 5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF-). Partial response (PR) requires ≥ 50% reduction in serum myeloma protein and ≥ 90% reduction of urine myeloma protein on at least 2 occasions for a minimum of at least 6 weeks along with stable bone disease and normal calcium. Near complete response (nCR) was defined as meeting all the criteria for complete response including 100% reduction in M-protein by protein electrophoresis; however, M-protein was still detectable by immunofixation (IF+).

Table 13: Summary of Efficacy Analyses in the Relapsed Multiple Myeloma Study

Efficacy Endpoint All Patients 1 Prior Line of Therapy > 1 Prior Line of Therapy
VELCADE
n=333
Dex
n=336
VELCADE
n=132
Dex
n=119
VELCADE
n=200
Dex
n=217
Time to Progression Events n (%) 147 (44) 196 (58) 55 (42) 64 (54) 92 (46) 132 (61)
Mediana (95% CI) 6.2 mo (4.9, 6.9) 3.5 mo (2.9, 4.2) 7.0 mo (6.2, 8.8) 5.6 mo (3.4, 6.3) 4.9 mo (4.2, 6.3) 2.9 mo (2.8, 3.5)
Hazard ratiob (95% CI) 0.55 (0.44, 0.69) 0.55 (0.38, 0.81) 0.54 (0.41, 0.72)
p-valuec < 0.0001 0.0019 < 0.0001
Overall Survival
Events (deaths) n (%) 51 (15) 84 (25) 12 (9) 24 (20) 39 (20) 60 (28)
Hazard ratiob (95% CI) 0.57 (0.40, 0.81) 0.39 (0.19, 0.81) 0.65 (0.43, 0.97)
p-valuec,d < 0.05 < 0.05 < 0.05
Response Rate Populatione n = 627 n=315 n=312 n=128 n=110 n=187 n=202
CRfn (%) 20 (6) 2 (<1) 8 (6) 2 (2) 12 (6) 0 (0)
PRf n(%) 101 (32) 54 (17) 49 (38) 27 (25) 52 (28) 27 (13)
nCRf,g n(%) 21 (7) 3 (<1) 8 (6) 2 (2) 13 (7) 1 (<1)
CR + PRf n (%) 121 (38) 56 (18) 57 (45) 29 (26) 64 (34) 27 (13)
p-valueh < 0.0001 0.0035 < 0.0001

aKaplan-Meier estimate
bHazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for VELCADE
cp-value based on the stratified log-rank test including randomization stratification factors
dPrecise p-value cannot be rendered
eResponse population includes patients who had measurable disease at baseline and received at least 1 dose of study drug
fEBMT criteria; nCR meets all EBMT criteria for CR but has positive IF. Under EBMT criteria nCR is in the PR category
gIn 2 patients, the IF was unknown
hp-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors

TTP was statistically significantly longer on the VELCADE arm (see Figure 3).

Figure 3: Time to Progression
Bortezomib versus Dexamethasone (relapsed multiple myeloma study)

Time to Progression Bortezomib versus Dexamethasone - Illustration

As shown in Figure 4 VELCADE had a significant survival advantage relative to dexamethasone (p < 0.05). The median follow-up was 8.3 months.

Figure 4: Overall Survival
Bortezomib versus Dexamethasone (relapsed multiple myeloma study)

Overall Survival Bortezomib versus Dexamethasone -  Illustration

For the 121 patients achieving a response (CR or PR) on the VELCADE arm, the median duration was 8.0 months (95% CI: 6.9, 11.5 months) compared to 5.6 months (95% CI: 4.8, 9.2 months) for the 56 responders on the dexamethasone arm. The response rate was significantly higher on the VELCADE arm regardless of β2microglobulin levels at baseline.

Randomized, Open-Label Clinical Study of VELCADE Subcutaneous versus Intravenous in Relapsed Multiple Myeloma

An open-label, randomized, phase 3 non-inferiority study compared the efficacy and safety of the subcutaneous administration of VELCADE versus the intravenous administration. This study included 222 bortezomib na´ve patients with relapsed multiple myeloma, who were randomized in a 2:1 ratio to receive 1.3 mg/m²of VELCADE by either the subcutaneous (n=148) or intravenous (n=74) route for 8 cycles. Patients who did not obtain an optimal response (less than Complete Response (CR)) to therapy with VELCADE alone after 4 cycles were allowed to receive oral dexamethasone 20 mg daily on the day of and after VELCADE administration (82 patients in subcutaneous treatment group and 39 patients in the intravenous treatment group). Patients with baseline Grade ≥ 2 peripheral neuropathy or neuropathic pain, or platelet counts < 50,000/μL were excluded. A total of 218 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had received (1 previous line versus more than 1 line of therapy), and international staging system (ISS) stage (incorporating beta2-microglobulin and albumin levels; Stages I, II, or III).

The baseline demographic and others characteristics of the two treatment groups are summarized as follows: the median age of the patient population was approximately 64 years of age (range 38-88 years), primarily male (subcutaneous: 50%, intravenous: 64%); the primary type of myeloma is IgG (subcutaneous: 65% IgG, 26% IgA, 8% light chain; intravenous: 72% IgG, 19% IgA, 8% light chain), ISS staging I/II/III (%) was 27, 41, 32 for both subcutaneous and intravenous, Karnofsky performance status score was ≤ 70% in 22% of subcutaneous and 16% of intravenous, creatinine clearance was 67.5 mL/min in subcutaneous and 73 mL/min in intravenous, the median years from diagnosis was 2.68 and 2.93 in subcutaneous and intravenous respectively and the proportion of patients with more than one prior line of therapy was 38% in subcutaneous and 35% in intravenous.

This study met its primary (non-inferiority) objective that single agent subcutaneous VELCADE retains at least 60% of the overall response rate after 4 cycles relative to single agent intravenous VELCADE. The results are provided in Table 14.

Table 14: Summary of Efficacy Analyses in the Relapsed Multiple Myeloma Study of VELCADE Subcutaneous versus Intravenous

Intent to Treat Population Subcutaneous VELCADE
n=148
Intravenous VELCADE
n=74
Primary Endpoint
Response Rate at 4 cycles
    ORR (CR+PR) n(%) 63 (43) 31 (42)
  Ratio of Response Rates (95% CI) 1.01 (0.73, 1.40)
    CR n (%) 11 (7) 6 (8)
    PR n (%) 52 (35) 25 (34)
    nCR n (%) 9 (6) 4 (5)
Secondary Endpoints
Response Rate at 8 cycles
    ORR (CR+PR) 78 (53) 38 (51)
    CR n (%) 17 (11) 9 (12)
    PR n (%) 61 (41) 29 (39)
    nCR n (%) 14 (9) 7 (9)
Median Time to Progression, months 10.4 9.4
Median Progression Free Survival, months 10.2 8
1-year Overall Survival (%)a 72.6 76.7
a Median duration of follow up is 11.8 months

A Randomized Phase 2 Dose-Response Study in Relapsed Multiple Myeloma

An open-label, multicenter study randomized 54 patients with multiple myeloma who had progressed or relapsed on or after front-line therapy to receive VELCADE 1 mg/m²or 1.3 mg/m²intravenous bolus twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21). The median duration of time between diagnosis of multiple myeloma and first dose of VELCADE on this trial was 2.0 years, and patients had received a median of 1 prior line of treatment (median of 3 prior therapies). A single complete response was seen at each dose. The overall response rates (CR + PR) were 30% (8/27) at 1 mg/m²and 38% (10/26) at 1.3 mg/m².

A Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma

Patients from the two phase 2 studies, who in the investigators' opinion would experience additional clinical benefit, continued to receive VELCADE beyond 8 cycles on an extension study. Sixty-three (63) patients from the phase 2 multiple myeloma studies were enrolled and received a median of 7 additional cycles of VELCADE therapy for a total median of 14 cycles (range 7 to 32). The overall median dosing intensity was the same in both the parent protocol and extension study. Sixty-seven percent (67%) of patients initiated the extension study at the same or higher dose intensity at which they completed the parent protocol, and 89% of patients maintained the standard 3-week dosing schedule during the extension study. No new cumulative or new long-term toxicities were observed with prolonged VELCADE treatment [see ADVERSE REACTIONS].

Mantle Cell Lymphoma

A Phase 2 Single-arm Clinical Study in Relapsed Mantle Cell Lymphoma After Prior Therapy

The safety and efficacy of VELCADE in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicenter study of 155 patients with progressive disease who had received at least 1 prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and 92% were Caucasian. Of the total, 75% had one or more extra-nodal sites of disease, and 77% were stage 4. In 91% of the patients, prior therapy included all of the following: an anthracycline or mitoxantrone, cyclophosphamide, and rituximab. A total of thirty seven percent (37%) of patients were refractory to their last prior therapy. An intravenous bolus injection of VELCADE 1.3 mg/m²/dose was administered twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21) for a maximum of 17 treatment cycles. Patients achieving a CR or CRu were treated for 4 cycles beyond first evidence of CR or CRu. The study employed dose modifications for toxicity [see DOSAGE AND ADMINISTRATION].

Responses to VELCADE are shown in Table 15. Response rates to VELCADE were determined according to the International Workshop Response Criteria (IWRC) based on independent radiologic review of CT scans. The median number of cycles administered across all patients was 4; in responding patients the median number of cycles was 8. The median time to response was 40 days (range 31 to 204 days). The median duration of follow-up was more than 13 months.

Table 15: Response Outcomes in a Phase 2 Mantle Cell Lymphoma Study

Response Analyses (N = 155) N (%) 95% CI
Overall Response Rate (IWRC) (CR + CRu + PR) 48 (31) (24, 39)
  Complete Response (CR + CRu) 12 (8) (4, 13)
     CR 10 (6) (3, 12)
     CRu 2 (1) (0, 5)
  Partial Response (PR) 36 (23) (17, 31)
Duration of Response Median 95% CI
     CR + CRu + PR (N = 48) 9.3 months (5.4, 13.8)
     CR + CRu (N = 12) 15.4 months (13.4, 15.4)
     PR (N=36) 6.1 months (4.2, 9.3)

Last reviewed on RxList: 11/6/2012
This monograph has been modified to include the generic and brand name in many instances.

A A A

Velcade - User Reviews

Velcade User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Velcade sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.

Health Resources
Related Supplements
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations